GB0100762D0 - Novel use - Google Patents

Novel use

Info

Publication number
GB0100762D0
GB0100762D0 GBGB0100762.4A GB0100762A GB0100762D0 GB 0100762 D0 GB0100762 D0 GB 0100762D0 GB 0100762 A GB0100762 A GB 0100762A GB 0100762 D0 GB0100762 D0 GB 0100762D0
Authority
GB
United Kingdom
Prior art keywords
novel use
novel
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
GBGB0100762.4A
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
SmithKline Beecham Ltd
Original Assignee
SmithKline Beecham Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by SmithKline Beecham Ltd filed Critical SmithKline Beecham Ltd
Priority to GBGB0100762.4A priority Critical patent/GB0100762D0/en
Publication of GB0100762D0 publication Critical patent/GB0100762D0/en
Priority to PCT/EP2002/000112 priority patent/WO2002055077A1/en
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/498—Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
GBGB0100762.4A 2001-01-11 2001-01-11 Novel use Ceased GB0100762D0 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
GBGB0100762.4A GB0100762D0 (en) 2001-01-11 2001-01-11 Novel use
PCT/EP2002/000112 WO2002055077A1 (en) 2001-01-11 2002-01-07 Use of imidazolyl cyclic acetal derivatives in the manufacture of a medicament for the treatment of diseases mediated by the alk5 receptors

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB0100762.4A GB0100762D0 (en) 2001-01-11 2001-01-11 Novel use

Publications (1)

Publication Number Publication Date
GB0100762D0 true GB0100762D0 (en) 2001-02-21

Family

ID=9906675

Family Applications (1)

Application Number Title Priority Date Filing Date
GBGB0100762.4A Ceased GB0100762D0 (en) 2001-01-11 2001-01-11 Novel use

Country Status (2)

Country Link
GB (1) GB0100762D0 (en)
WO (1) WO2002055077A1 (en)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR039241A1 (en) * 2002-04-04 2005-02-16 Biogen Inc HETEROARILOS TRISUSTITUIDOS AND METHODS FOR ITS PRODUCTION AND USE OF THE SAME
GB0217783D0 (en) * 2002-07-31 2002-09-11 Glaxo Group Ltd Compounds
JP4518956B2 (en) 2002-09-18 2010-08-04 ファイザー・プロダクツ・インク Novel triazole and oxazole compounds as transforming growth factor (TGF) inhibitors
CA2498047C (en) 2002-09-18 2009-05-19 Pfizer Products Inc. Novel imidazole compounds as transforming growth factor (tgf) inhibitors
BR0314302A (en) 2002-09-18 2005-07-05 Pfizer Producs Inc Pyrazole Compounds as Transforming Growth Factor (TGF) Inhibitors
WO2004026865A1 (en) 2002-09-18 2004-04-01 Pfizer Products Inc. Novel isothiazole and isoxazole compounds as transforming growth factor (tgf) inhibitors
BR0314577A (en) 2002-09-18 2005-08-09 Pfizer Prod Inc Triazole derivatives as transforming growth factor (tgf) inhibitors
PA8595001A1 (en) 2003-03-04 2004-09-28 Pfizer Prod Inc NEW CONDENSED HETEROAROMATIC COMPOUNDS THAT ARE INHIBITORS OF THE TRANSFORMING GROWTH FACTOR (TGF)
JP4688483B2 (en) 2004-04-15 2011-05-25 株式会社テクノネットワーク四国 Follistatin variant polypeptide
US20080319012A1 (en) 2004-04-21 2008-12-25 In2Gen Co., Ltd. 2-Pyridyl substituted imidazoles as ALK5 and/or ALK4 inhibitors
US8513222B2 (en) 2010-06-29 2013-08-20 EWHA University—Industry Collaboration Foundation Methods of treating fibrosis, cancer and vascular injuries
US8080568B1 (en) 2010-06-29 2011-12-20 Ewha University - Industry Collaboration Foundation 2-pyridyl substituted imidazoles as therapeutic ALK5 and/or ALK4 inhibitors
USRE47141E1 (en) 2010-06-29 2018-11-27 EWHA University—Industry Collaboration Foundation Methods of treating fibrosis, cancer and vascular injuries
EP2731949B1 (en) 2011-07-13 2018-04-04 TiumBio Co., Ltd. 2-pyridyl substituted imidazoles as alk5 and/or alk4 inhibitors
CN103724276A (en) * 2013-12-13 2014-04-16 成都丽璟科技有限公司 Novel method for preparing benzimidazole compounds from nitroaniline
CA3164037A1 (en) 2020-01-08 2021-07-15 Synthis Therapeutics, Inc. Alk5 inhibitor conjugates and uses thereof

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK0988301T3 (en) * 1997-06-12 2006-11-13 Aventis Pharma Ltd Imidazolylcyclic acetals
IL133766A0 (en) * 1997-06-30 2001-04-30 Ortho Mcneil Pharm Inc 2-substituted imidazoles useful in the treatment of inflammatory diseases
US6465493B1 (en) * 1999-04-09 2002-10-15 Smithkline Beecham Corporation Triarylimidazoles
AU5028500A (en) * 2000-05-19 2001-12-03 Us Gov Health & Human Serv Inhibition of smad3 to prevent fibrosis and improve wound healing

Also Published As

Publication number Publication date
WO2002055077A1 (en) 2002-07-18

Similar Documents

Publication Publication Date Title
HU0401339D0 (en) Novel 4-anilinoquinoline-3-carboxamides
EP1387687A4 (en) Novel use
GB0125088D0 (en) New use
GB0100762D0 (en) Novel use
GB0115181D0 (en) Novel use
EP1384783A4 (en) Novel maxizyme
GB0104554D0 (en) New uses
EG23036A (en) Novel pyrrolecarboxamides
GB0106031D0 (en) Use
PL367864A1 (en) Novel combination
GB0119920D0 (en) New use
PL364076A1 (en) Novel pyridylmethylaminopyrimidines
GB0100852D0 (en) Novel use
GB0129268D0 (en) Novel use
GB0129266D0 (en) Novel use
GB0119022D0 (en) Novel use
GB0118919D0 (en) Novel use
GB0103899D0 (en) Use
GB0126186D0 (en) Use
GB0102482D0 (en) Use
GB0103892D0 (en) Use
GB0108115D0 (en) Use
GB0130704D0 (en) New use
GB0112208D0 (en) New use
GB0129834D0 (en) New use

Legal Events

Date Code Title Description
AT Applications terminated before publication under section 16(1)